| abstract |
The invention relates to compounds of general formula (I) wherein R1 signifies hydrogen, lower alkyl or hydroxy-lower alkyl; R2 signifies furyl, thienyl, pyridyl or phenyl, which is optionally substituted by 1 to 3 substituents, selected from lower alkyl, lower alkoxy, halogen, cyano, CF¿3? or -N(R?4)¿2; R3 signifies naphthyl or phenyl, which is optionally substituted by 1 to 3 substituents, selected from lower alkyl, lower alkoxy, halogen, acetyl, cyano, hydroxy-lower alkyl, -CH¿2?-morpholin-4-yl, lower alkyl-oxy-lower alkyl, lower alkyl-N(R?4)¿2 or CF3; R4 signifies, independently from each other, hydrogen or lower alkyl, with the exception of (RS)-2-phenyl-1-(toluene-4-sulfonyl)-pyrrolidine and (RS)-1-(toluene-4-sulfonyl)-2-p-tolyl-pyrrolidine as well as their pharmaceutically acceptable salts. The compounds described above are metabotropic glutamate receptor antagonists or agonists and therefore useful in the treatment of corresponding CNS disorders. |